XKRX
256840
Market cap108mUSD
Jul 10, Last price
2,505.00KRW
1D
4.38%
1Q
-32.93%
IPO
-1.76%
Name
BNC Korea Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in South Korea, BNC Korea Co., Ltd. focuses on the research, development, manufacturing, and distribution of various biomaterials. The company's diverse product range features hyaluronic acid (HA) and skin booster fillers, including brand names like Cutegel, Cutegel Lidocaine, FLORE Lidocaine, ChungA-an, CUTEGEL-M, Cutegel Hydro, S-DNA, and H-DNA, all designed for the temporary reduction of facial wrinkles through physical restoration. Beyond aesthetic products, BNC Korea also manufactures Hibarry, a specialized dressing for deep-cavity wounds, which helps mitigate spinal cord adhesion during surgery. Another key medical product is GENTA Q, a white collagen sponge created to protect wounds by preventing contamination. Additionally, the company offers a line of beauty solutions, encompassing face mask gels, mild cleansing foams, and brightening peeling gels. With a significant international presence, BNC Korea exports its products to 45 countries. The firm was founded in 2007 and is headquartered in Daegu, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||